NASDAQ:CELU Celularity Q1 2026 Earnings Results & Report $0.61 -0.02 (-2.71%) As of 02:50 PM Eastern This is a fair market value price provided by Massive. Learn more. Celularity reported Q1 2026 earnings on September 29, 2026. The company reported EPS of $0.02, while revenue was $3.85 million. Research:ProfileEarnings HistoryForecast Earnings Announcement Details QuarterQ1 2026Report DateSeptember 29, 2026TimeAfter Market ClosesConference Call7:00 AM ET Celularity EPS ResultsActual EPS$0.02Consensus EPS N/ABeat/MissN/AOne Year Ago EPSN/AEPS Beat Rate6 of last 6 quartersCelularity Revenue ResultsActual Revenue$3.85 millionExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/AConference Call ResourcesQuarterly Report (10-Q)SEC FilingEarnings HistoryCompany ProfilePowered by Earnings DocumentsQuarterly report(10-Q) Celularity Q1 2026 Earnings FAQ Did Celularity beat earnings estimates for Q1 2026? Celularity (NASDAQ:CELU) reported earnings of $0.02 per share for Q1 2026. The report was announced on Tuesday, September 29, 2026. What was Celularity's revenue for Q1 2026? Celularity reported revenue of $3.85 million for Q1 2026. Celularity Earnings HeadlinesHead-To-Head Review: Celularity (NASDAQ:CELU) versus Upstream Bio (NASDAQ:UPB)November 7, 2026 | americanbankingnews.comCelularity, Vesalius announce peptide API manufacturing pact in Florham ParkOctober 31, 2026 | roi-nj.comRYour free book is about to disappearBill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time through a temporary download link. He plans to charge for it soon. Download your copy now and lock it in at no cost, regardless of future pricing.November 16 at 1:00 AM | Profits Run (Ad)Celularity Inc. announces exclusive peptide API manufacturing collaboration with Vesalius Longevity Labs on October 29, 2026October 29, 2026 | msn.comCelularity and Vesalius Longevity Labs Sign Exclusive Collaboration for Peptual® Peptide APIs Manufactured in the United StatesOctober 29, 2026 | finance.yahoo.comCelularity Regains Compliance with Nasdaq Periodic Reporting RequirementOctober 22, 2026 | globenewswire.comSee More Celularity Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Celularity? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Celularity and other key companies, straight to your email. Email Address About CelularityCelularity (NASDAQ:CELU) is a biotechnology company that develops cell therapies and other products derived from the human placenta. Its platform uses cells collected after childbirth, which the company processes for potential use in regenerative medicine and treatment of disease. The company’s research includes placental-derived natural killer cells and other cell types being developed for potential applications in cancer and other conditions. Its pipeline has included candidates such as CYNK-001, an investigational natural killer cell therapy. Founded in 2016, Celularity is headquartered in Florham Park, New Jersey. Its work focuses on developing and manufacturing placenta-derived products for clinical and commercial use.View Celularity ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Ondas Is Building a Defense Growth Engine, But Can It Deliver on Its Backlog?3 Building-Materials Stocks Rallying While Homebuilders Struggle to Find BuyersMarketBeat Week in Review – 11/9 - 11/133 AI Hardware Leaders Are Raising Dividends, But Which Offers More Income?Nu Holdings Earnings Show a Compounder Priced Like a Brazil BetCould Big Buybacks Be the Next Catalyst for These 3 AI Stocks?Cerebras Q3 Results: How Much More Proof Does Wall Street Need? Upcoming Earnings Walt Disney (11/17/2026)Home Depot (11/17/2026)NVIDIA (11/17/2026)Lowe's Companies (11/18/2026)TJX Companies (11/18/2026)Target (11/18/2026)Palo Alto Networks (11/18/2026)NetEase (11/19/2026)Alibaba Group (11/19/2026)PDD (11/19/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.